Tavneos Faces FDA Withdrawal Over Data Fraud and Liver Injury
The FDA approved the vasculitis treatment Tavneos in October 2021 despite significant doubts about its clinical trial evidence. Though the advisory committee voted narrowly to recommend approval, the underlying study showed only modest effectiveness with questionable data quality. Patients and some physicians viewed it as a potentially valuable option for reducing reliance on steroids, which are effective but often cause severe side effects.
The drug became commercially successful following Amgen’s acquisition of manufacturer ChemoCentryx one year after approval. By fiscal 2025, Tavneos sales reached nearly half a billion dollars annually, with the drug priced at $220,000 per year. An investor lawsuit later uncovered evidence that ChemoCentryx employees had manipulated clinical trial data before submitting it to the FDA. In April, the agency issued a letter proposing withdrawal from the market, citing reports of serious liver injury and concluding the drug now lacks adequate evidence of effectiveness.
Read the full article
Continue reading at Ars Technica →This is an AI-generated summary. Read the original for the full story.